Sera Prognostics (SERA) Stock Price, News & Analysis

+0.19 (+1.94%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
73,136 shs
Average Volume
218,358 shs
Market Capitalization
$323.00 million
P/E Ratio
Dividend Yield
Price Target

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
72.4% Downside
$2.75 Price Target
Short Interest
1.15% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$1.26 M Sold Last Quarter
Proj. Earnings Growth
From ($0.94) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.33 out of 5 stars

Medical Sector

843rd out of 909 stocks

Medical Laboratories Industry

20th out of 20 stocks

SERA stock logo

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

SERA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sera Prognostics Inc Class A
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Sera Prognostics: Q4 Earnings Insights
Sera Prognostics's Earnings Outlook
See More Headlines
Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.21 per share


Free Float
Market Cap
$323.00 million
Not Optionable
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Evguenia Lindgardt M.B.A. (Age 50)
    President, CEO & Director
    Comp: $37.5k
  • Dr. Gregory C. Critchfield M.D. (Age 71)
    M.S., Executive Director
    Comp: $790.74k
  • Dr. Steven W. Graves
    Co-Founder and Co-Chairman of The Scientific Advisory Board
  • Dr. M. Sean Esplin M.D.
    Co-Founder and Co-Chairman of Scientific Advisory Board
  • Mr. Austin Aerts
    Chief Financial Officer??
  • Dr. John J. Boniface Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $386.69k
  • Mr. Robert G. Harrison (Age 58)
    Chief Information Officer
    Comp: $384.18k
  • Mr. Benjamin G. Jackson J.D. (Age 45)
    General Counsel
    Comp: $410.75k
  • Dr. Paul Kearney Ph.D. (Age 56)
    Chief Data Officer

SERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SERA shares.
View SERA analyst ratings
or view top-rated stocks.

What is Sera Prognostics' stock price target for 2024?

2 analysts have issued twelve-month price objectives for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they expect the company's stock price to reach $2.75 in the next year. This suggests that the stock has a possible downside of 72.4%.
View analysts price targets for SERA
or view top-rated stocks among Wall Street analysts.

How have SERA shares performed in 2024?

Sera Prognostics' stock was trading at $5.98 on January 1st, 2024. Since then, SERA shares have increased by 66.6% and is now trading at $9.96.
View the best growth stocks for 2024 here

Are investors shorting Sera Prognostics?

Sera Prognostics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 198,600 shares, an increase of 71.5% from the March 15th total of 115,800 shares. Based on an average daily volume of 245,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.2% of the shares of the stock are sold short.
View Sera Prognostics' Short Interest

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SERA earnings forecast

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) announced its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.10 million. Sera Prognostics had a negative trailing twelve-month return on equity of 45.74% and a negative net margin of 11,843.79%.

What ETF holds Sera Prognostics' stock?

Invesco DWA SmallCap Momentum ETF holds 632,067 shares of SERA stock, representing 0.72% of its portfolio.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.06%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt.
View institutional ownership trends

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SERA) was last updated on 4/24/2024 by Staff

From Our Partners